The FDA Is Going After an Opioid Painkiller for the First Time

The agency requested that a pharma company take its drug off the market.

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.

Last Thursday, for the first time in history, the Food and Drug Administration asked a pharmaceutical company to take an opioid painkiller off the market. The agency found that the benefits of the medication, Opana ER, were outweighed by its risks: It is frequently snorted and injected, and linked to HIV outbreaks, the spread of hepatitis C, and a blood clotting disorder called thrombotic microangiopathy.

“We are facing an opioid epidemic—a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse,” said FDA Commissioner Dr. Scott Gottlieb in a statement. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said Gottlieb.

The FDA’s request may indicate that the commissioner, accused of cozy relationships with pharmaceutical companies, is taking a tough stance on painkiller prescribing, which has laid the foundation for today’s soaring overdose epidemic. “I am pleased, but not because I think that this one move by itself will have much impact,” says Dr. Andrew Kolodny, who researches opioid policy at Brandeis University and directs Physicians for Responsible Opioid Prescribing. “I’m hopeful that this signals a change at FDA—and that Opana might be just the first opioid that they’ll consider taking off the market. It’s too soon to tell.”

Opana ER (for extended release) was created by Endo Pharmaceuticals and approved by the FDA in 2006. After finding that drug users crushed and snorted the drug, taking in 12 hours worth of medication instantaneously, Endo introduced a reformulated version in 2012, which had a hard shell that Endo claimed made the drug more difficult to abuse. This decision may have been motivated by more than just public safety—as NPR noted, Endo faced loss of patent protection without a reformulation. But the FDA found that the reformulation made abuse more likely than the former version: instead of snorting it, users took to injecting it—leading to a cluster of thrombotic microangiopathy deaths in Tennessee in 2012 and Indiana’s HIV outbreak in 2014 and 2015.

The FDA’s decision doesn’t necessarily indicate that Opana ER is more abusable than other opioid painkillers still on the market, but rather that it is riskier than the previous (now generic) version. In fact, Opana ER is chemically similar to a number of other painkillers, notes Kolodny. High dosage painkiller pills in particular are easily abused: Without tolerance to opioids, experimenting with one 80-milligram OxyContin pill or Subsys prescription fentanyl spray could cause an overdose. Critics worry that even “abuse-deterrent” versions of painkillers, which typically are harder to crush or dissolve and are marketed as a safe alternative to other opioids, are still abusable. “Abuse-deterrent formulations are no less addictive and no less effective and they are mostly going to take our eye off the ball,” says Dr. Caleb Alexander, co-director of Johns Hopkins University’s Center for Drug Safety and Effectiveness.

Whether or not Endo will comply remains to be seen; the company is “evaluating the full range of potential options as we determine the appropriate path forward,” according to a prepared statement. Since last Thursday’s announcement, its stock price has plummeted by nearly 20 percent. If Endo doesn’t pull its product, the FDA “intends to take steps to formally require its removal by withdrawing approval,” according to a press release.

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

WE'LL BE BLUNT

It is astonishingly hard keeping a newsroom afloat these days, and we need to raise $253,000 in online donations quickly, by October 7.

The short of it: Last year, we had to cut $1 million from our budget so we could have any chance of breaking even by the time our fiscal year ended in June. And despite a huge rally from so many of you leading up to the deadline, we still came up a bit short on the whole. We can’t let that happen again. We have no wiggle room to begin with, and now we have a hole to dig out of.

Readers also told us to just give it to you straight when we need to ask for your support, and seeing how matter-of-factly explaining our inner workings, our challenges and finances, can bring more of you in has been a real silver lining. So our online membership lead, Brian, lays it all out for you in his personal, insider account (that literally puts his skin in the game!) of how urgent things are right now.

The upshot: Being able to rally $253,000 in donations over these next few weeks is vitally important simply because it is the number that keeps us right on track, helping make sure we don't end up with a bigger gap than can be filled again, helping us avoid any significant (and knowable) cash-flow crunches for now. We used to be more nonchalant about coming up short this time of year, thinking we can make it by the time June rolls around. Not anymore.

Because the in-depth journalism on underreported beats and unique perspectives on the daily news you turn to Mother Jones for is only possible because readers fund us. Corporations and powerful people with deep pockets will never sustain the type of journalism we exist to do. The only investors who won’t let independent, investigative journalism down are the people who actually care about its future—you.

And we need readers to show up for us big time—again.

Getting just 10 percent of the people who care enough about our work to be reading this blurb to part with a few bucks would be utterly transformative for us, and that's very much what we need to keep charging hard in this financially uncertain, high-stakes year.

If you can right now, please support the journalism you get from Mother Jones with a donation at whatever amount works for you. And please do it now, before you move on to whatever you're about to do next and think maybe you'll get to it later, because every gift matters and we really need to see a strong response if we're going to raise the $253,000 we need in less than three weeks.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate